Illumina Launches World's Largest Genome Dataset to Accelerate Drug Discovery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: PRnewswire
- Dataset Scale: Illumina's Billion Cell Atlas aims to create a 5 billion cell genomic dataset over three years, designed to accelerate drug discovery through AI, significantly enhancing R&D efficiency in the pharmaceutical industry.
- Partnership Framework: Collaborating with AstraZeneca, Merck, and Eli Lilly, the Atlas will utilize over 200 disease-relevant cell lines for drug target validation and AI model training, advancing the development of precision medicine.
- Data Processing Capability: The Atlas is set to generate 20 petabytes of single-cell transcriptomic data annually, processed using Illumina's DRAGEN pipeline and cloud platform, ensuring scalable and efficient data analysis to expedite drug development decisions.
- Biological Insights: Utilizing CRISPR technology, the Atlas will capture responses of 1 billion cells to genetic changes, aiding in the understanding of complex disease mechanisms and facilitating the translation from genetic signals to drug development with increased confidence and speed.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ILMN is 124.12 USD with a low forecast of 40.50 USD and a high forecast of 195.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
Current: 145.300
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
